Next Article in Journal
Update in Systemic and Targeted Therapies in Gastrointestinal Oncology
Next Article in Special Issue
Progress in Adenoviral Capsid-Display Vaccines
Previous Article in Journal
Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets
Previous Article in Special Issue
The Repertoire of Adenovirus in Human Disease: The Innocuous to the Deadly
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessReview
Biomedicines 2018, 6(1), 33; https://doi.org/10.3390/biomedicines6010033

Oncolytic Adenoviruses in Gastrointestinal Cancers

1
Department of Medicine, Division of Hematology Oncology, Mayo Clinic Arizona, 13400 E Shea Blvd, Scottsdale, AZ 85205, USA
2
Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA
3
Center for Individualized Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
4
Mayo Clinic Cancer Center, 5881 E Mayo Blvd, Phoenix, AZ 85054, USA
*
Author to whom correspondence should be addressed.
Received: 31 January 2018 / Revised: 5 March 2018 / Accepted: 9 March 2018 / Published: 11 March 2018
(This article belongs to the Special Issue Adenoviruses: From Virus to Medicine)
Full-Text   |   PDF [208 KB, uploaded 11 March 2018]   |  

Abstract

Gastrointestinal malignancies are challenging cancers with considerable economic and societal impacts on health care systems worldwide. While advances in surgical approaches have provided benefits to a proportion of patients, only modest improvements have been attained in the treatment of patients with advanced disease, resulting in limited improvement in survival rates in these patients. Oncolytic adenoviruses are being developed to address gastrointestinal malignancies. Each platform has evolved to maximize tumor-cell killing potency while minimizing toxicities. Tumor-specific bioengineered adenoviruses using chimeric promoters, prodrug convertase enzymes, lethal genes, tumor suppressor genes, and pseudo-typed capsids can provide the innovations for eventual success of oncolytic virotherapy. This article will review the developments in adenoviral platforms in the context of specific gastrointestinal cancers. From the bench to the implementation of clinical trials, this review aims to highlight advances in the field from its early days to the current state of affairs as it pertains to the application of adenoviral oncolytic therapy to gastrointestinal cancers. View Full-Text
Keywords: adenovirus; oncovirotherapy; assessment of adeno-vector safety; gastrointestinal cancers; oncolytic therapy adenovirus; oncovirotherapy; assessment of adeno-vector safety; gastrointestinal cancers; oncolytic therapy
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Yokoda, R.T.; Nagalo, B.M.; Borad, M.J. Oncolytic Adenoviruses in Gastrointestinal Cancers. Biomedicines 2018, 6, 33.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top